| __timestamp | Amicus Therapeutics, Inc. | Amneal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 106735000 |
| Thursday, January 1, 2015 | 76943000 | 136870000 |
| Friday, January 1, 2016 | 104793000 | 204747000 |
| Sunday, January 1, 2017 | 149310000 | 191938000 |
| Monday, January 1, 2018 | 270902000 | 210451000 |
| Tuesday, January 1, 2019 | 286378000 | 202287000 |
| Wednesday, January 1, 2020 | 308443000 | 190585000 |
| Friday, January 1, 2021 | 272049000 | 209563000 |
| Saturday, January 1, 2022 | 276677000 | 200046000 |
| Sunday, January 1, 2023 | 152381000 | 167778000 |
Unleashing insights
In the competitive world of biopharmaceuticals, innovation is key. Amicus Therapeutics, Inc. and Amneal Pharmaceuticals, Inc. have been at the forefront of this race since 2014. Over the past decade, Amicus Therapeutics has consistently outpaced Amneal in research and development (R&D) spending, with a peak in 2020 where their investment was approximately 62% higher than Amneal's. This trend highlights Amicus's commitment to pioneering new therapies, particularly in rare diseases. Meanwhile, Amneal's R&D expenditure has remained relatively stable, reflecting a more conservative approach. Notably, in 2023, both companies saw a decline in R&D spending, with Amicus reducing its investment by nearly 50% from its 2020 peak. This shift could signal a strategic pivot or market pressures. As the industry evolves, these investment patterns will be crucial in determining which company leads the next wave of pharmaceutical innovation.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
AstraZeneca PLC vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
R&D Insights: How Incyte Corporation and Amneal Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amneal Pharmaceuticals, Inc. and MannKind Corporation
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV